Fate Therapeutics logo

Fate Therapeutics Share Price Today

(NASDAQ: FATE)

Fate Therapeutics share price is $0.91 & ₹79.14 as on 6 Mar 2025, 2.30 'hrs' IST

$0.91

-0.04

(-4.73%)

Market is closed - opens 8 PM, 06 Mar 2025

View live Fate Therapeutics share price in Dollar and Rupees. Guide to invest in Fate Therapeutics stock from India, including Indian investor sentiment. Get details on Indian mutual funds investing in Fate Therapeutics, along with analyst recommendations, forecasts, and comprehensive financials.

Fate Therapeutics share price movements

  • Today's Low: $0.89
    Today's High: $0.96

    Day's Volatility :7.1%

  • 52 Weeks Low: $0.89
    52 Weeks High: $8.83

    52 Weeks Volatility :89.93%

Fate Therapeutics (FATE) Returns

PeriodFate Therapeutics IncSector (Health Care)Index (Russel 2000)
3 Months
-61.97%
3.7%
0.0%
6 Months
-74.5%
-2.8%
0.0%
1 Year
-88.66%
2.5%
0.0%
3 Years
-97.16%
12.9%
-11.6%

Fate Therapeutics (FATE) Key Statistics

in dollars & INR

Previous Close
$0.95
Open
$0.96
Today's High
$0.9567
Today's Low
$0.8888
Market Capitalization
$103.1M
Today's Volume
$3.4M
52 Week High
$8.83
52 Week Low
$0.8888
Revenue TTM
$13.4M
EBITDA
$-164.7M
Earnings Per Share (EPS)
$-1.64
Profit Margin
0.0%
Quarterly Earnings Growth YOY
0.0%
Return On Equity TTM
-46.59%

How to invest in Fate Therapeutics Stock (FATE) from India?

It is very easy for Indian residents to invest directly in Fate Therapeutics from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Fate Therapeutics stock in both Indian Rupees (INR) and US Dollars (USD). Search for Fate Therapeutics or FATE on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Fate Therapeutics or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Fate Therapeutics shares which would translate to 0.956 fractional shares of Fate Therapeutics as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Fate Therapeutics, in just a few clicks!

Returns in Fate Therapeutics (FATE) for Indian investors in Rupees

The Fate Therapeutics stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Fate Therapeutics investment value today

Current value as on today

₹16,352

Returns

₹83,648

(-83.65%)

Returns from Fate Therapeutics Stock

₹88,596 (-88.6%)

Dollar Returns

₹4,949 (+4.95%)

Indian investors sentiment towards Fate Therapeutics (FATE)

-21%

Period: Feb 3, 2025 to Mar 5, 2025. Change in 30 Days versus previous period

Search interest for Fate Therapeutics Stock from India on INDmoney has decreased by -21% in the last 30 days, reflecting a downward trend in search activity.

Global Institutional Holdings in Fate Therapeutics

  • Redmile Group, LLC

    11.30%

  • BlackRock Inc

    9.61%

  • Vanguard Group Inc

    9.07%

  • Boxer Capital LLC

    4.36%

  • Bellevue Group AG

    4.25%

  • Citadel Advisors Llc

    3.85%

Analyst Recommendation on Fate Therapeutics

Hold

    42%Buy

    53%Hold

    3%Sell

Based on 26 Wall street analysts offering stock ratings for Fate Therapeutics(by analysts ranked 0 to 5 stars)

Based on 26 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
11
11
11
Hold
14
14
14
Sell
1
1
1

Analyst Forecast on Fate Therapeutics Stock (FATE)

What analysts predicted

Upside of 595.97%

Target:

$6.33

Current:

$0.91

Insights on Fate Therapeutics Stock (Ticker Symbol: FATE)

  • Price Movement

    In the last 7 days, FATE stock has moved down by -17.0%
  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 6.77M → 3.07M (in $), with an average decrease of 54.6% per quarter
  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, -38.42M → -47.67M (in $), with an average decrease of 24.1% per quarter
  • FATE vs ALNY (1 yr)

    In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 66.5% return, outperforming this stock by 155.2%
  • FATE vs VRTX (3 yr)

    In the last 3 years, Vertex Pharmaceuticals Incorporated has given 51.6% return, outperforming this stock by 148.8%
  • Price to Sales

    ForFATE every $1 of sales, investors are willing to pay $7.4, whereas for Alnylam Pharmaceuticals, Inc., the investors are paying $14.2 for every $1 of sales.

FATE Fate Therapeutics Financials in INR & Dollars

FY18Y/Y Change
Revenue
$4.7M
↑ 15.44%
Net Income
$-66.6M
↑ 55.05%
Net Profit Margin
-1.4K%
↓ 358.94%
FY19Y/Y Change
Revenue
$10.7M
↑ 125.32%
Net Income
$-97.7M
↑ 46.71%
Net Profit Margin
-914.87%
↑ 490.15%
FY20Y/Y Change
Revenue
$31.4M
↑ 194.33%
Net Income
$-170.3M
↑ 74.29%
Net Profit Margin
-541.77%
↑ 373.1%
FY21Y/Y Change
Revenue
$55.8M
↑ 77.66%
Net Income
$-206.3M
↑ 21.14%
Net Profit Margin
-369.41%
↑ 172.36%
FY22Y/Y Change
Revenue
$96.3M
↑ 72.44%
Net Income
$-255.1M
↑ 23.63%
Net Profit Margin
-264.86%
↑ 104.55%
FY23Y/Y Change
Revenue
$63.5M
↓ 34.03%
Net Income
$-160.9M
↓ 36.9%
Net Profit Margin
-253.3%
↑ 11.56%
Q2 FY23Q/Q Change
Revenue
$933.0K
↓ 98.42%
Net Income
$-52.8M
↑ 475.3%
Net Profit Margin
-5.7K%
↓ 5638.79%
Q3 FY23Q/Q Change
Revenue
$1.9M
↑ 108.36%
Net Income
$-45.2M
↓ 14.38%
Net Profit Margin
-2.3K%
↑ 3330.78%
Q4 FY23Q/Q Change
Revenue
$1.7M
↓ 13.79%
Net Income
$-44.1M
↓ 2.32%
Net Profit Margin
-2.6K%
↓ 309.02%
Q1 FY24Q/Q Change
Revenue
$1.9M
↑ 14.86%
Net Income
$-48.0M
↑ 8.8%
Net Profit Margin
-2.5K%
↑ 138.87%
Q2 FY24Q/Q Change
Revenue
$6.8M
↑ 251.79%
Net Income
$-38.4M
↓ 19.95%
Net Profit Margin
-567.44%
↑ 1926.27%
Q3 FY24Q/Q Change
Revenue
$3.1M
↓ 54.61%
Net Income
$-47.7M
↑ 24.07%
Net Profit Margin
-1.6K%
↓ 983.57%
FY18Y/Y Change
Profit
$4.7M
↑ 15.44%
FY19Y/Y Change
Profit
$-77.1M
↓ 1726.37%
FY20Y/Y Change
Profit
$-94.2M
↑ 22.18%
FY21Y/Y Change
Profit
$50.0M
↓ 153.08%
FY22Y/Y Change
Profit
$96.3M
↑ 92.62%
FY23Y/Y Change
Profit
$-98.2M
↓ 201.93%
Q2 FY23Q/Q Change
Profit
$-3.5M
↓ 106.45%
Q3 FY23Q/Q Change
Profit
$-2.8M
↓ 20.86%
Q4 FY23Q/Q Change
Profit
$-3.2M
↑ 14.77%
Q1 FY24Q/Q Change
Profit
$-2.9M
↓ 9.75%
Q2 FY24Q/Q Change
Profit
$-27.8M
↑ 861.05%
Q3 FY24Q/Q Change
Profit
$3.1M
↓ 111.04%
FY18Y/Y Change
Operating Cash Flow
$-38.7M
↑ 4.73%
Investing Cash Flow
$-463.0K
↓ 95.46%
Financing Cash Flow
$140.8M
↑ 196.73%
FY19Y/Y Change
Operating Cash Flow
$-83.2M
↑ 115.2%
Investing Cash Flow
$-157.5M
↑ 33907.13%
Financing Cash Flow
$149.9M
↑ 6.5%
FY20Y/Y Change
Operating Cash Flow
$-39.2M
↓ 52.84%
Investing Cash Flow
$-161.1M
↑ 2.3%
Financing Cash Flow
$282.8M
↑ 88.65%
FY21Y/Y Change
Operating Cash Flow
$-162.9M
↑ 315.18%
Investing Cash Flow
$-324.0M
↑ 101.16%
Financing Cash Flow
$453.1M
↑ 60.21%
FY22Y/Y Change
Operating Cash Flow
$-248.2M
↑ 52.4%
Investing Cash Flow
$166.8M
↓ 151.46%
Financing Cash Flow
$9.2M
↓ 97.97%
Q2 FY23Q/Q Change
Operating Cash Flow
$-28.5M
↓ 1.27%
Investing Cash Flow
$33.2M
↑ 255.11%
Financing Cash Flow
$58.0K
↓ 71.98%

Fate Therapeutics Technicals Summary

Sell

Neutral

Buy

Fate Therapeutics is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Fate Therapeutics (FATE) Vs Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Fate Therapeutics Inc logo
-30.91%
-74.5%
-88.66%
-97.16%
-96.36%
Regeneron Pharmaceuticals, Inc. logo
-1.42%
-40.28%
-29.31%
11.08%
44.83%
Beone Medicines Ltd logo
17.63%
36.87%
64.37%
45.89%
71.3%
Vertex Pharmaceuticals Incorporated logo
1.94%
4.92%
19.37%
108.73%
123.83%
Alnylam Pharmaceuticals, Inc. logo
-8.03%
-0.89%
66.53%
52.9%
126.66%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Fate Therapeutics Inc logo
NA
NA
0.0
-1.65
-0.47
-0.22
NA
3.18
Regeneron Pharmaceuticals, Inc. logo
17.86
17.86
1.01
43.09
0.16
0.07
0.01
273.57
Beone Medicines Ltd logo
NA
NA
NA
1.43
-0.19
-0.06
NA
31.22
Vertex Pharmaceuticals Incorporated logo
32.84
NA
1.34
18.07
-0.03
0.13
NA
63.87
Alnylam Pharmaceuticals, Inc. logo
NA
NA
-0.49
0.57
-15.01
-0.03
NA
0.52
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Fate Therapeutics Inc logo
Hold
$103.1M
-96.36%
NA
0.0%
Regeneron Pharmaceuticals, Inc. logo
Buy
$73.8B
44.83%
17.86
31.07%
Beone Medicines Ltd logo
NA
$29.1B
71.3%
NA
-16.92%
Vertex Pharmaceuticals Incorporated logo
Buy
$124.9B
123.83%
32.84
-4.86%
Alnylam Pharmaceuticals, Inc. logo
Buy
$31.4B
126.66%
NA
-12.37%

About Fate Therapeutics

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.
Organization
Fate Therapeutics
Employees
181
CEO
Dr. Bahram Valamehr M.B.A., Ph.D.
Industry
Health Technology

Management People of Fate Therapeutics

NameTitle
Dr. Bahram Valamehr M.B.A., Ph.D.
President & CEO
Ms. Cindy R. Tahl J.D.
Chief Legal & Compliance Officer and Corporate Secretary
Dr. Jerome Bressi Ph.D.
Chief Regulatory & Quality Officer
Mr. Andrew Henry
Senior Vice President of Clinical Operations

Important FAQs about investing in FATE Stock from India :

What is Fate Therapeutics share price today?

Fate Therapeutics share price today stands at $0.91, Open: $0.96 ; Previous Close: $0.95 ; High: $0.96 ; Low: $0.89 ; 52 Week High: $8.83 ; 52 Week Low: $0.89.

The stock opens at $0.96, after a previous close of $0.95. The stock reached a daily high of $0.96 and a low of $0.89, with a 52-week high of $8.83 and a 52-week low of $0.89.

Can Indians buy Fate Therapeutics shares?

Yes, Indians can invest in the Fate Therapeutics (FATE) from India.

With INDmoney, you can buy Fate Therapeutics at 0 brokerage. The step-by-step process is as follows:

  • Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
  • Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
  • Once funds are transferred successfully, you can buy Fate Therapeutics at zero transaction cost.

How can I buy Fate Therapeutics shares from India?

It is very easy to buy Fate Therapeutics from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Fate Therapeutics (FATE) be purchased?

Yes, you can buy fractional shares of Fate Therapeutics with INDmoney app.

What are the documents required to start investing in Fate Therapeutics stocks?

To start investing in Fate Therapeutics, You will need the following documents:

  • Proof of Identification (PAN, Aadhaar etc)
  • Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.

What are today’s High and Low prices of Fate Therapeutics Stock (FATE)?

Today’s highest price of Fate Therapeutics (FATE) is $0.96.

Today’s lowest price of Fate Therapeutics (FATE) is $0.89.

What is today's market capitalisation of Fate Therapeutics?

Today's market capitalisation of Fate Therapeutics FATE is 103.1M

What is the 52 Week High and Low Range of Fate Therapeutics Stock (FATE)?

  • 52 Week High

    $8.83

  • 52 Week Low

    $0.89

What are the historical returns of Fate Therapeutics (FATE)?

  • 1 Month Returns

    -30.91%

  • 3 Months Returns

    -74.5%

  • 1 Year Returns

    -88.66%

  • 5 Years Returns

    -96.36%

Who is the Chief Executive Officer (CEO) of Fate Therapeutics ?

Dr. Bahram Valamehr M.B.A., Ph.D. is the current Chief Executive Officer (CEO) of Fate Therapeutics.